Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20
Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.
Read original at benzingaStocks · News reference
Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20
Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and raises the price target from $19 to $20.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 1:59 PM
- Checked
- Aug 7, 2026, 1:59 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Amphastar Pharma Q2 Adj. EPS $0.91 Beats $0.62 Estimate, Sales $183.903M Beat $182.055M Estimate
Amphastar Pharma (NASDAQ:AMPH) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.62 by 46.77 percent. This is a 7.06 percent increase over earnings of $0.85 per share from
Read original at benzingaTwo Years to Build or Pay 200% — Which US Pharma Stocks Win?
Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
Read original at benzinga